A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

Clinical Colorectal Cancer - United States
doi 10.1016/j.clcc.2018.01.011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Breast Care
SurgeryOncology
2011English

Correction: A Phase II Trial of 1st-Line Modified-Folfoxiri Plus Bevacizumab Treatment for Metastatic Colorectal Cancer Harboring RAS Mutation: JACCRO CC-11

Oncotarget
Oncology
2018English

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

Oncologist
Cancer ResearchMedicineOncology
2019English

Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Discontinuation of First-Line Bevacizumab in Metastatic Colorectal Cancer: The BEAWARE Italian Observational Study

Tumori
MedicineCancer ResearchOncology
2019English

Bevacizumab in First-Line Treatment of Elderly Patients With Metastatic Colorectal Cancer: German Community-Based Observational Cohort Study Results

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy